eMedicine Specialties > Pulmonology > Interstitial Lung Diseases

Pulmonary Fibrosis, Idiopathic: Multimedia

Author: Javier I Diaz, MD,, Fellow in Interventional Pulmonology, Henry Ford Hospital
Coauthor(s): Daniel R Ouellette, MD, FCCP, Associate Professor of Medicine, Wayne State University School of Medicine; Consulting Staff, Pulmonary Disease and Critical Care Medicine Service, Henry Ford Health System
Contributor Information and Disclosures

Updated: Jun 30, 2009

Multimedia

Chest radiograph of a patient with idiopathic pul...Media file 1: Chest radiograph of a patient with idiopathic pulmonary fibrosis showing bilateral lower-lobe reticular opacities (red circles).
Chest radiograph of a patient with idiopathic pul...

Chest radiograph of a patient with idiopathic pulmonary fibrosis showing bilateral lower-lobe reticular opacities (red circles).

Classic honeycombing (red circle) in a patient wi...Media file 2: Classic honeycombing (red circle) in a patient with a diagnosis of idiopathic pulmonary fibrosis
Classic honeycombing (red circle) in a patient wi...

Classic honeycombing (red circle) in a patient with a diagnosis of idiopathic pulmonary fibrosis

Patient with a diagnosis of usual interstitial pn...Media file 3: Patient with a diagnosis of usual interstitial pneumonia. Note the reticular opacities (red circle) distributed in both lung bases, with minimal ground-glass opacities (blue circles).
Patient with a diagnosis of usual interstitial pn...

Patient with a diagnosis of usual interstitial pneumonia. Note the reticular opacities (red circle) distributed in both lung bases, with minimal ground-glass opacities (blue circles).

Patient with nonspecific interstitial pneumonitis...Media file 4: Patient with nonspecific interstitial pneumonitis. Note the predominance of ground-glass opacities (blue circle) and some reticular lines (red arrow).
Patient with nonspecific interstitial pneumonitis...

Patient with nonspecific interstitial pneumonitis. Note the predominance of ground-glass opacities (blue circle) and some reticular lines (red arrow).

Patchwork distribution of abnormalities in a clas...Media file 5: Patchwork distribution of abnormalities in a classic example of usual interstitial pneumonitis (low-magnification photomicrograph; hematoxylin and eosin stain; original magnification, X4). Courtesy of Chad Stone, MD.
Patchwork distribution of abnormalities in a clas...

Patchwork distribution of abnormalities in a classic example of usual interstitial pneumonitis (low-magnification photomicrograph; hematoxylin and eosin stain; original magnification, X4). Courtesy of Chad Stone, MD.

More on Pulmonary Fibrosis, Idiopathic

Overview: Pulmonary Fibrosis, Idiopathic
Differential Diagnoses & Workup: Pulmonary Fibrosis, Idiopathic
Treatment & Medication: Pulmonary Fibrosis, Idiopathic
Follow-up: Pulmonary Fibrosis, Idiopathic
Multimedia: Pulmonary Fibrosis, Idiopathic
References

References

  1. Verma S, Slutsky AS. Idiopathic pulmonary fibrosis--new insights. N Engl J Med. Mar 29 2007;356(13):1370-2. [Medline].

  2. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. Oct 1 2006;174(7):810-6. [Medline].

  3. Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med. Aug 1 2007;176(3):277-84. [Medline].

  4. Patel NM, Lederer DJ, Borczuk AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest. Sep 2007;132(3):998-1006. [Medline].

  5. Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. Jan 2006;27(1):136-42. [Medline].

  6. Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc. Jun 2006;3(4):285-92. [Medline].

  7. Hyzy R, Huang S, Myers J, Flaherty K, Martinez F. Acute exacerbation of idiopathic pulmonary fibrosis. Chest. Nov 2007;132(5):1652-8. [Medline].

  8. Loyd JE. Pulmonary fibrosis in families. Am J Respir Cell Mol Biol. Sep 2003;29(3 Suppl):S47-50. [Medline].

  9. Lawson WE, Loyd JE. The genetic approach in pulmonary fibrosis: can it provide clues to this complex disease?. Proc Am Thorac Soc. Jun 2006;3(4):345-9. [Medline].

  10. Antoniou KM, Hansell DM, Rubens MB, Marten K, Desai SR, Siafakas NM, et al. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med. Jan 15 2008;177(2):190-4. [Medline].

  11. Silva CI, Müller NL, Lynch DA, Curran-Everett D, Brown KK, Lee KS, et al. Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT. Radiology. Jan 2008;246(1):288-97. [Medline].

  12. Misumi S, Lynch DA. Idiopathic pulmonary fibrosis/usual interstitial pneumonia: imaging diagnosis, spectrum of abnormalities, and temporal progression. Proc Am Thorac Soc. Jun 2006;3(4):307-14. [Medline].

  13. Thannickal VJ, Horowitz JC. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc. Jun 2006;3(4):350-6. [Medline].

  14. Flaherty KR, Thwaite EL, Kazerooni EA, Gross BH, Toews GB, Colby TV, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax. Feb 2003;58(2):143-8. [Medline].

  15. Erbes R, Schaberg T, Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome?. Chest. Jan 1997;111(1):51-7. [Medline].

  16. Jegal Y, Kim DS, Shim TS, Lim CM, Do Lee S, Koh Y, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. Mar 15 2005;171(6):639-44. [Medline].

  17. Martinez FJ, Flaherty K. Pulmonary function testing in idiopathic interstitial pneumonias. Proc Am Thorac Soc. Jun 2006;3(4):315-21. [Medline].

  18. Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, King TE Jr. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest. Jan 2008;133(1):226-32. [Medline].

  19. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. Jan 8 2004;350(2):125-33. [Medline].

  20. [Best Evidence] King TE, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. Jun 2009;[Full Text].

  21. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. May 1 2005;171(9):1040-7. [Medline].

  22. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. Nov 24 2005;353(21):2229-42. [Medline].

  23. Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, et al. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. Jul 2006;25(7):745-55. [Medline].

  24. Daniels CE, Ryu JH. Treatment of idiopathic pulmonary fibrosis. Semin Respir Crit Care Med. Dec 2006;27(6):668-76. [Medline].

  25. Flaherty KR, Andrei AC, King TE Jr, Raghu G, Colby TV, Wells A, et al. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?. Am J Respir Crit Care Med. May 15 2007;175(10):1054-60. [Medline].

  26. Gay SE, Kazerooni EA, Toews GB, Lynch JP 3rd, Gross BH, Cascade PN, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med. Apr 1998;157(4 Pt 1):1063-72. [Medline].

  27. Gharaee-Kermani M, Gyetko MR, Hu B, Phan SH. New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy. Pharm Res. May 2007;24(5):819-41. [Medline].

  28. Hunninghake GW, Kalica AR. Approaches to the treatment of pulmonary fibrosis. Am J Respir Crit Care Med. Mar 1995;151(3 Pt 1):915-8. [Medline].

  29. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. Apr 1998;157(4 Pt 1):1301-15. [Medline].

  30. King TE Jr. Idiopathic pulmonary fibrosis. In: Schwarz MI, King TE Jr, eds. Interstitial Lung Disease. St. Louis, Mo: Mosby; 1993:367-403.

  31. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. Jun 21 2005;142(12 Pt 1):963-7. [Medline].

  32. Noth I, Martinez FJ. Recent advances in idiopathic pulmonary fibrosis. Chest. Aug 2007;132(2):637-50. [Medline].

  33. Visscher DW, Myers JL. Histologic spectrum of idiopathic interstitial pneumonias. Proc Am Thorac Soc. Jun 2006;3(4):322-9. [Medline].

Further Reading

Keywords

idiopathic pulmonary fibrosis, IPF, cryptogenic fibrosing alveolitis, usual interstitial pneumonitis, UIP, interstitial disease, intersitial lung disease, desquamative interstitial pneumonitis, DIP, cor pulmonale, pneumothorax, thromboembolism disease, thromboembolic disease, chronic fibrosing alveolitis, fibrosing alveolitis, Hamman-Rich syndrome, collagen-vascular disease, collagen vascular disease, alveolar injuries, alveolar injury, inflammation of the lung parenchyma, fibrosis of the lung parenchyma, Ebstein-Barr virus, chronic aspiration secondary to gastroesophageal reflux

Contributor Information and Disclosures

Author

Javier I Diaz, MD,, Fellow in Interventional Pulmonology, Henry Ford Hospital
Disclosure: Nothing to disclose.

Coauthor(s)

Daniel R Ouellette, MD, FCCP, Associate Professor of Medicine, Wayne State University School of Medicine; Consulting Staff, Pulmonary Disease and Critical Care Medicine Service, Henry Ford Health System
Daniel R Ouellette, MD, FCCP is a member of the following medical societies: American College of Chest Physicians and American Thoracic Society
Disclosure: Boehringer Ingleheim Honoraria Speaking and teaching; Pfizer Honoraria Speaking and teaching

Medical Editor

Stephen P Peters, MD, PhD, Professor, Department of Medicine, Wake Forest University
Stephen P Peters, MD, PhD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Association of Immunologists, American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, American Thoracic Society, and Sigma Xi
Disclosure: See below for list of all activities None None

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Daniel R Ouellette, MD, FCCP, Associate Professor of Medicine, Wayne State University School of Medicine; Consulting Staff, Pulmonary Disease and Critical Care Medicine Service, Henry Ford Health System
Daniel R Ouellette, MD, FCCP is a member of the following medical societies: American College of Chest Physicians and American Thoracic Society
Disclosure: Boehringer Ingleheim Honoraria Speaking and teaching; Pfizer Honoraria Speaking and teaching

CME Editor

Timothy D Rice, MD, Associate Professor, Departments of Internal Medicine and Pediatrics and Adolescent Medicine, Saint Louis University School of Medicine
Timothy D Rice, MD is a member of the following medical societies: American Academy of Pediatrics and American College of Physicians
Disclosure: Nothing to disclose.

Chief Editor

Zab Mosenifar, MD, Director, Division of Pulmonary and Critical Care Medicine, Director, Women's Guild Pulmonary Disease Institute, Executive Vice Chair, Department of Medicine, Cedars Sinai Medical Center; Professor of Medicine, David Geffen School of Medicine at UCLA
Zab Mosenifar, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, and American Thoracic Society
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.